[Phorbol-12-myristate-13-acetate and interferon-gamma synergistic induction of B7-1 expression in ovary carcinoma cells and immunological value].
OBJECTIVE
To investigate the therapeutic potential of phorbol-12-myristate-13-acetate(PMA) and interferon-gamma(IFN-gamma) by induction of expression of adhesion molecule in mucious cystadenocarcinoma of ovary (MCAS) and other tumor cells.


METHODS
Expression of costimulatory signals(B7-1), major histocompatibility complex(MHC-I, MHC-II) was analysed with flow cytometry. Cytotoxic T lymphocytes(CTL) killing activity and T cell proliferation induced with expression of B7-1 were evaluated by 4-h 51Cr release assay and standard 3HTdR incorporation and scintitation counting.


RESULTS
Pretreatment with PMA and then treated with IFN-gamma was able to enhance B7-1 expression on the tumor cell lines with the constitutive B7-1 expression or on B7-1-transfected tumor cells and to induce B7-1 expression on MCAS and some tumor cell lines without constitutive B7-1 expression. However, treatment with IFN-gamma alone failed to induce B7-1 expression on the tumor cell lines. The synergistic effect of PMA combined with IFN-gamma in the induction of B7-1 expression can be anatagonised by H7 [1-(5-isoquinolinesulfonyl)-2-methyl-Piperazine dihydrochloride]. In addition, treatment with PMA combined with IFN-gamma simultaneously induced or enhanced the expression of MHC class I/II on these tumor cell lines. The tumor cells treated by PMA combined with IFN-gamma were able to induce CTL killing activity and T cell proliferation, which is involved in the expression of B7-1.


CONCLUSIONS
The enhancement or induction of B7-1 expression by IFN-gamma may be dependent on the prior activation of protein kinase by PMA and the induced B7-1 expression on tumor cells may have some therapeutic potential.
Zhao
X
X
Department of Obstetrics and Gynecology, Second University Hospital, West China University of Medical Sciences, Chengdu 610041.
Wei
Y
Y
Peng
Z
Z
D018122:B7-1 Antigen / Q000096:biosynthesis*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D018282:Cystadenocarcinoma, Mucinous / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D018122:B7-1 Antigen; D007371:Interferon-gamma; D013755:Tetradecanoylphorbol Acetate